The COVID-19 pandemic: Is it a turning point for E-health?: CON

por Möller, H.-J.
Publicado 2021

Affective disorders: the role of the duration of untreated illness, suicidality and pharmacogenetics

por Falkai, P., Möller, H.-J.
Publicado 2010

The use of atypical antipsychotics in Bipolar Spectrum disorders

por Grünze, H., Möller, H.J.
Publicado 2003

Biomarkers, population-based studies and a proof of principle investigation in pharmacotherapy

por Falkai, P., Möller, H.-J.
Publicado 2010

The psychosis continuum: diagnosis and other phenotypes

por Möller, H. J., Falkai, P.
Publicado 2011

The functional sequelae of schizophrenia: consequences of long-term pharmacotherapy and the neurobiology of addiction

por Falkai, P., Möller, H.-J.
Publicado 2011

Pain, affect and psychotic illness

por Möller, H.-J., Falkai, P.
Publicado 2011

Achievement and maintenance of the new impact factor 2010

por Falkai, P., Möller, H.-J.
Publicado 2011

From generation of biomarkers to treatment and psychosocial aspects of psychosis

por Falkai, P., Möller, H.-J.
Publicado 2011

Mood disorders in the light of genes, comorbidity and contemporary treatment

por Falkai, P., Möller, H.-J.
Publicado 2011

Emotional status: diagnosis and treatment for severe psychiatric disorders

por Falkai, P., Möller, H.-J.
Publicado 2011

Neurobiology of schizophrenia: from outcome to pathophysiological insights

por Falkai, P., Möller, H. -J.
Publicado 2012

Vagal Nerve Stimulation-Modulation of the Anti-Inflammatory Response and Clinical Outcome in Psoriatic Arthritis or Ankylosing Spondylitis

por Brock, C., Rasmussen, S. E., Drewes, A. M., Møller, H. J., Brock, B., Deleuran, B., Farmer, A. D., Pfeiffer-Jensen, M.
Publicado 2021